R

Arcus Biosciences
D

RCUS

11.070
USD
0.34
(3.17%)
Market Closed
Volume
52,724
EPS
-5
Div Yield
-
P/E
-3
Market Cap
1,163,988,061
Related Instruments
    A
    ARWR
    -1.040
    (-4.97%)
    19.900 USD
    C
    CRIS
    -0.03400
    (-1.09%)
    3.07600 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    K
    KPTI
    -0.00940
    (-1.55%)
    0.59840 USD
    R
    RCKT
    -0.390
    (-3.59%)
    10.470 USD
    More
News

Title: Arcus Biosciences

Sector: Healthcare
Industry: Biotechnology
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.